Screener
Cullinan Therapeutics, Inc. CGEM Total Revenue
Discontinued — last reported Q4 '22
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Cullinan Therapeutics, Inc.’s 10-K, filed March 9, 2023.
- Filed
- Mar 9, 2023
- Fiscal year
- FY2022
- Accession
- 0000950170-23-006839
| Line item | Year Ended December 31, 2022 | Year Ended December 31, 2021 |
|---|---|---|
| License revenue | — | $18,943 |
| Operating expenses: | ||
| Research and development | 91,948 | 57,751 |
| General and administrative | 40,189 | 29,146 |
| Total operating expenses | 132,137 | 86,897 |
| Gain on sale of Cullinan Pearl | 276,785 | — |
| Income (loss) from operations | 144,648 | (67,954) |
| Other income (expense): |
Item 16. Form 10-K Summary.
FAQ
- What is Cullinan Therapeutics, Inc.'s total revenue?
- Cullinan Therapeutics, Inc. (CGEM) reported total revenue of $0 in Q4 2022.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Cullinan Therapeutics, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude